Previous studies have shown that people with obesity have a higher risk of getting cancer, in part because their
).
Dr. Andrew Hogan and his team at the Lonsdale Health Institute at Maynooth University have discovered through new Health Research Board (HRB)-funded research that the well-known and highly effective pharmacological treatment for obesity, glucagon-like peptide (GLP-1) analogs, can actually restore NK cell function in the body, including its capacity to eradicate cancerous cells.
Dr. Andrew E. Hogan, Associate Professor and Principal Investigator, at Lonsdale Human Health Institute in Maynooth University, discussed the findings: “My team and I are very excited by these new findings in relation to the effects of the GLP-1 treatment on people with obesity, and it appears to result in real, tangible benefits for those currently on the drug.
Advertisement
“While these findings will understandably be welcomed by those living with obesity and looking for safe and effective treatments, given the recent spike in popularity related to the benefits of the GLP-1 treatment with global and high-profile celebrities commenting on its success, global demand has increased and resulted in a worldwide shortage of the drug.”
Prevalence of Obesity Among Cancer Patients
According to the World Health Organization, 13% of adults worldwide are obese, a condition associated with an increased risk of developing cancer. These cancers comprise about 40% of all cancers diagnosed in the United States each year (3✔ ✔Trusted Source
Obesity and overweight
Go to source
).
GLP-1: The Cancer Killing Engine
The study also demonstrates that GLP-1’s primary role in weight loss is not necessary for the restored ability of NK cells to fight cancer, suggesting that the medication is likely directly igniting the NK cells’ engine.
“I hope this is something that is brought under control to ensure as many people as possible living with obesity can start their own treatment with this beneficial drug.”
“People with obesity can develop a variety of health problems like type 2 diabetes, sleep apnea, and cancer. These can have very negative impacts on their quality of life. This research and other promising findings on improvements in cardiovascular health after GLP-1 therapy indicate its potential benefits in addition to weight loss.” said, Conor de Barra, a Ph.D. student in immunology at Maynooth University and an Irish Research Council Scholar who led the work in Dr. Hogan’s lab.
Prof. Donal O’Shea, HSE National Lead for Obesity and Principal Investigator, said: “We are finally reaching the point where medical treatments for the disease of obesity are being shown to prevent the complications of having obesity. The current findings represent very positive news for people living with obesity on GLP-1 therapy and suggest the benefits of this family of treatments may extend to a reduction in cancer risk.”
References :
- Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function – (https://onlinelibrary.wiley.com/doi/10.1002/oby.23772)
- Obesity-Associated Alterations of Natural Killer Cells and Immunosurveillance of Cancer – (https://pubmed.ncbi.nlm.nih.gov/32231659/)
- Obesity and overweight – (https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)
Source: Medindia
Source link
#Cure #Obesity #Cancer
